2024-07-15 03:59:45 ET
Summary
- Larimar Therapeutics' stock has surged 50% after its FA therapy was selected for FDA's START program, aiming for a BLA filing in 2H25.
- Its lead candidate Nomlabofusp is a protein replacement therapy for Friedreich's ataxia, competing with Biogen's Skyclarys and other potential treatments.
- Larimar has enough cash to fund operations until 2026, with analyst optimism and a timeline to potentially beat competitors to the market.
- Can the recent rally in the shares continue? A full investment analysis follows in the paragraphs below.
Shares of rare disease concern Larimar Therapeutics Inc. ( LRMR ) have rallied approximately 50% after its lead (and only) clinical program (nomlabofusp) was selected for the FDA’s START program on May 30th. The admission strengthens management’s belief that it will be able to file a BLA in 2H25, extending a good run that started with FDA fully lifting a long-standing partial clinical hold on May 20th. With a registrational trial still to conduct, enough cash to get it through its BLA submission timeline but one solid competitor only a year behind, this clinical stage biotech concern merited a deeper dive. An analysis follows below....
Read the full article on Seeking Alpha
For further details see:
Larimar Therapeutics: More Data Still Needed